- AuthorisedTherapeutic confirmatory (Phase III)
ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases
This study, called ALADDIN, looks at a new drug (darolutamide - BAY 1841788) alongside standard hormones and radiotherapy for men with newly diagnosed prostate cancer that has spread to nearby lymph nodes. It aims to see if adding this drug helps them live longer without their cancer getting worse.
For: Newly diagnosed prostate cancer with pelvic lymph nodes metastasesFrance - AuthorisedTherapeutic exploratory (Phase II)
Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts
This study is looking at a new way to treat prostate cancer that has spread. It compares two different drug combinations to see which is better at stopping the cancer from growing for at least four months.
For: prostate cancerItaly - AuthorisedTherapeutic confirmatory (Phase III)
OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women
This study, OPTIMA YOUNG, is for younger women with a common type of early breast cancer. It looks at the best way to treat this cancer to stop it from coming back, by comparing different medications and how well they work.
For: Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.Poland · France · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
SAFIR 03_A ctDNA screening program in patients with HR+, HER2- metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations.
For: Metastatic Breast Cancer HR+ · HER2-France